Multiple electrolyte abnormalities after pamidronate administration.
Pamidronate constitutes a major advance in the treatment of tumor-associated hypercalcemia. However, transient electrolyte abnormalities have been reported after pamidronate administration. We describe here a patient with multiple myeloma and severe hypercalcemia who developed transient but significant electrolyte disturbances (mainly hypophosphatemia and hypomagnesemia) after a single dose of 90 mg of pamidronate, focusing on the underlying pathophysiological mechanisms.
Elisaf
M
M
Department of Internal Medicine, University of Ioannina Medical School, Greece.
Kalaitzidis
R
R
Siamopoulos
K C
KC
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002118:Calcium / Q000097:blood; D002128:Calcium Metabolism Disorders / Q000097:blood / Q000139:chemically induced; D004164:Diphosphonates / Q000009:adverse effects*; D004573:Electrolytes / Q000097:blood*; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced*; D008274:Magnesium / Q000097:blood*; D008297:Male; D008875:Middle Aged; D000077268:Pamidronate; D010281:Parathyroid Hormone / Q000097:blood
D000970:Antineoplastic Agents; D004164:Diphosphonates; D004573:Electrolytes; D010281:Parathyroid Hormone; D008274:Magnesium; D000077268:Pamidronate; D002118:Calcium